|
Market Closed -
Nasdaq
21:00:00 23/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 39.31 USD | -1.70% |
|
+5.70% | +58.41% |
| 10-16 | William Blar Initiates Coverage on Edgewise Therapeutics With Outperform Rating | MT |
| 10-08 | Edgewise Therapeutics Doses First Patient in Trial of Investigational Heart Failure Drug | MT |
| Market Cap | 4.27B 3.81B 3.52B 3.19B 5.97B 405B 6.07B 42.38B 16.78B 212B 16.02B 15.68B 669B | P/E 2026 * |
22.5x | P/E 2027 * | -19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 3.01B 2.69B 2.48B 2.25B 4.21B 286B 4.28B 29.88B 11.83B 150B 11.3B 11.06B 472B | EV / Sales 2026 * |
23.4x | EV / Sales 2027 * | 80.5x |
| Free-Float |
99.51% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| EWTX | Delayed | |
CBOE
| EWTX | Real-time |
Last Transcript: Edgewise Therapeutics, Inc.
| 1 day | -1.70% | ||
| 1 week | +5.70% | ||
| Current month | -3.18% | ||
| 1 month | -4.24% | ||
| 3 months | +0.05% | ||
| 6 months | +25.87% | ||
| Current year | +58.41% |
| 1 week | 36.54 |  | 40.78 |
| 1 month | 35.63 | | 42.12 |
| Current year | 22.78 | | 48.51 |
| 1 year | 15.23 | | 48.51 |
| 3 years | 5.12 | | 48.51 |
| 5 years | 5.12 | | 48.51 |
| 10 years | 5.12 | | 48.51 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alan Russell
CTO | Chief Tech/Sci/R&D Officer | 56 | 31/05/2017 |
Kevin Koch
CEO | Chief Executive Officer | 65 | 31/07/2017 |
Michael Nofi
DFI | Director of Finance/CFO | 55 | 09/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Koch
BRD | Director/Board Member | 65 | 31/05/2017 |
Peter Thompson
CHM | Chairman | 67 | 31/07/2017 |
Alan Russell
BRD | Director/Board Member | 56 | 31/07/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/10/26 | Free | Director | 308 | 0.0003% | ||
| 13/08/26 | Sell | Chief Technology Officer | -2,919 | 0.0027% | ||
| 12/08/26 | Free | Chief Financial Officer | 48,750 | 0.0453% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.70% | +5.70% | +160.33% | +484.10% | 4.27B | |
| +2.41% | +0.29% | +42.02% | +71.57% | 64.69B | |
| -0.15% | +7.50% | +11.01% | +73.48% | 54.78B | |
| +0.57% | +4.60% | +10.07% | +92.86% | 53.49B | |
| +0.37% | +4.67% | +27.03% | +52.07% | 45.98B | |
| -1.21% | +2.32% | +21.80% | +123.81% | 42.94B | |
| -0.37% | +5.07% | +249.91% | +918.74% | 40.08B | |
| +0.05% | +0.21% | +18.26% | +58.53% | 33.52B | |
| -0.38% | +5.68% | +36.43% | +27.54% | 23.67B | |
| +1.19% | -4.98% | +29.01% | -0.65% | 23.97B | |
| Average | +0.08% | +2.74% | +60.59% | +190.20% | 38.74B | |
| Weighted average by Cap. | +0.37% | +2.76% | +48.81% | +162.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 129M 115M 106M 96.33M 180M 12.23B 183M 1.28B 506M 6.41B 484M 473M 20.2B | 39.17M 34.98M 32.31M 29.28M 54.78M 3.72B 55.69M 389M 154M 1.95B 147M 144M 6.14B |
| Net income | 210M 188M 174M 157M 294M 19.97B 299M 2.09B 827M 10.46B 790M 773M 32.99B | -220M -196M -181M -164M -307M -20.84B -312M -2.18B -863M -10.92B -824M -806M -34.43B |
| Net Debt | -1.26B -1.12B -1.04B -941M -1.76B -120B -1.79B -12.5B -4.95B -62.62B -4.72B -4.62B -197B | -1.12B -998M -922M -835M -1.56B -106B -1.59B -11.09B -4.39B -55.57B -4.19B -4.1B -175B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/10/26 | US$39.31 | -1.70% | 911,110 |
| 22/10/26 | US$39.99 | +0.86% | 1,337,725 |
| 21/10/26 | US$39.65 | -0.25% | 1,828,373 |
| 20/10/26 | US$39.75 | +4.83% | 2,171,190 |
| 19/10/26 | US$37.92 | +1.96% | 1,421,580 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EWTX Stock
Select your edition
All financial news and data tailored to specific country editions
